The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 07, 2023

Filed:

May. 06, 2016
Applicants:

The Children's Medical Center Corporation, Boston, MA (US);

The Broad Institute, Inc., Cambridge, MA (US);

Massachusetts Institute of Technology, Cambridge, MA (US);

Inventors:

Daniel E. Bauer, Cambridge, MA (US);

Stuart H. Orkin, Brookline, MA (US);

Neville Sanjana, New York, NY (US);

Ophir Shalem, Albany, CA (US);

Feng Zhang, Cambridge, MA (US);

Assignees:
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12N 5/078 (2010.01); C12N 15/10 (2006.01); C12N 9/22 (2006.01); C12N 15/11 (2006.01); C12N 15/86 (2006.01);
U.S. Cl.
CPC ...
C12N 5/0641 (2013.01); C12N 9/22 (2013.01); C12N 15/102 (2013.01); C12N 15/11 (2013.01); C12N 15/86 (2013.01); C12N 2310/20 (2017.05); C12N 2510/00 (2013.01); C12N 2740/15041 (2013.01);
Abstract

Provided herein are nucleic acid molecules that target the BCL11A enhancer functional regions, compositions comprising the nucleic acid molecules and methods for increasing fetal hemoglobin levels in a cell by disrupting BCL11A expression at the genomic level. Also provided herein are methods and compositions relating to the treatment of hemoglobinopathies by reinduction of fetal hemoglobin levels. In particular, the nucleic acid molecules target the +62, +58, and/or the +55 enhancer functional regions.


Find Patent Forward Citations

Loading…